Landmark Study Reveals Medicinal Cannabis Falls Short for Anxiety, Depression, and PTSD
The most comprehensive review of medicinal cannabis to date finds little evidence it helps mental health conditions — and may actually cause harm.
Medicinal Cannabis Shows No Real Benefit for Common Mental Health Conditions
Despite millions of people turning to medicinal cannabis to manage anxiety, depression, and post-traumatic stress disorder, the most extensive scientific review ever conducted on the subject has found it simply does not work for these conditions. Even more concerning, researchers warn it could actively worsen mental health outcomes for some users.
Published in the prestigious medical journal The Lancet, the study analyzed data from 54 randomized controlled trials carried out across the globe over a 45-year span from 1980 to 2025. The findings represent the most thorough assessment of both the safety and effectiveness of cannabinoid-based treatments across a broad spectrum of mental health disorders.
Widespread Use Driven by Unproven Beliefs
The scale of medicinal cannabis use makes these findings particularly significant. Approximately 27 percent of individuals between the ages of 16 and 65 in the United States and Canada report using cannabis for medical purposes. Strikingly, around half of those users say their primary motivation is to manage mental health symptoms — a practice the new research suggests may be doing more harm than good.
Lead researcher Dr. Jack Wilson of the University of Sydney's Matilda Centre expressed serious concern about the routine approval of cannabis-based treatments for mental health applications.
"Though our paper didn't specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes — for example, a greater risk of psychotic symptoms and developing cannabis use disorder — and delaying the use of more effective treatments," Dr. Wilson stated.
Where Cannabis May Offer Some Help
The review was not entirely negative. Researchers identified a handful of conditions where medicinal cannabis showed at least limited promise. These include:
- Cannabis use disorder (dependency on cannabis itself)
- Autism spectrum conditions
- Insomnia
- Tics associated with Tourette's syndrome
However, Dr. Wilson was quick to caution that the quality of evidence supporting these applications remains weak.
"The overall quality of evidence for conditions such as autism and insomnia was low. In the absence of robust medical or counseling support, the use of medicinal cannabis in these cases is rarely justified," he said.
The study did acknowledge that cannabinoid treatments have demonstrated clearer benefits in certain non-psychiatric medical contexts — including reducing seizures linked to specific forms of epilepsy, easing spasticity in multiple sclerosis patients, and managing particular types of chronic pain. However, these benefits do not extend to mental health disorders based on current evidence.
On the topic of autism specifically, Dr. Wilson noted that while some symptom reduction was observed, findings should be interpreted carefully given the highly individual nature of the condition.
Mixed Outcomes for Substance Use Disorders
When it came to substance use disorders, the results were more nuanced. Cannabis-based treatments showed genuine potential for individuals struggling with cannabis dependency itself — an approach that draws comparison to how methadone is used in treating opioid addiction. When combined with psychological therapy, an oral cannabis formulation was shown to reduce cannabis smoking behavior.
On the other hand, the results for cocaine-use disorder told a very different story. Rather than helping, medicinal cannabis actually intensified cravings in people with cocaine dependency.
"When medicinal cannabis was used to treat people with cocaine-use disorder, it increased their cravings. This means it should not be considered for this purpose and may, in fact, worsen cocaine dependence," Dr. Wilson explained.
Growing Calls for Stricter Oversight
The rapid expansion of medicinal cannabis prescribing has already raised red flags among prominent medical bodies, including the American Medical Association. Critics point to inconsistent regulation and a persistent lack of reliable safety data as key issues that urgently need to be addressed.
Dr. Wilson emphasized that the study's goal is to give healthcare providers a solid, independent evidence base to guide their decisions.
"Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support clinicians in making evidence-based decisions — helping to ensure patients receive effective treatments while minimizing harm from ineffective or unsafe cannabis products," he said.
What This Means Going Forward
As cannabis legalization and medical access continue to expand across North America and beyond, this research delivers a timely and sobering reality check. For the millions who have turned to cannabis to ease anxiety, depression, or PTSD, the scientific evidence does not support its effectiveness — and the potential risks, including addiction and psychosis, are real.
Healthcare professionals and policymakers alike are being urged to prioritize evidence-based treatments and push for stronger regulatory frameworks governing the prescription and use of medicinal cannabis products.
